Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling, often irreversible toxicity that affects millions of patients, limits life-saving cancer therapy, and lacks proven treatment. In this ...

electroCore (Nasdaq: ECOR) submitted a 510(k) notification to the FDA seeking clearance of Quell for chronic chemotherapy-induced peripheral neuropathy (CIPN).The submission draws on 168 subjects in a randomized controlled trial and an open-label study. Neuropathic pain scores decreased approximately 40% with active treatment versus approximately 24-33% with sham treatment. A non-pre-specified analysis of subjects with moderate to severe baseline pain showed decreases of approximately 50% versus approximately 30%.In the 142-subject randomized trial, neuropathy questionnaire scores improved 11.6% with Quell versus 8.7% with sham, meeting the preliminary study’s pre-specified statistical significance threshold of 0.2. In the open-label study, 22 completers showed 13% improvement over six weeks. Quell-related adverse events were generally infrequent, mild and self-limiting. FDA clearance remains pending.

A randomized phase 2 trial evaluated whether prophylactic goshajinkigan reduces the incidence of CIPN in patients receiving carboplatin plus paclitaxel.

Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling, often irreversible toxicity that affects millions of patients, limits life-saving cancer therapy, and lacks proven treatment. In this ...

Cancer treatment continues to evolve worldwide, creating significant demand for supportive care solutions that improve patient outcomes and quality of life. Across the global healthcare landscape, chemotherapy induced peripheral neuropathy (CIPN) has emerged as one of the most common complications associated with cancer treatment, encouraging greater attention from pharmaceutical companies, healthcare providers, and research organizations. As oncology care advances and the number of patients receiving chemotherapy continues to grow, the global…

YouTube video by Gaveta

YouTube video by Spanish with James

MIRA's oral NMDA receptor modulator enters IRB review for a first-in-indication Phase 2a study in chemotherapy-induced peripheral neuropathy.

A psychedelic compound best known for its effects on the brain may help prevent one of chemotherapy's most debilitating side effects – chemotherapy-induced peripheral neuropathy (CIPN), rese...

PJ.2.1,Huge declines in learning across OECD countries, Norway doctors see 3x children with memory problems, Serum Cu/Zn ratio and Long COVID, 3rd Pennsylvania measles death, Psilocybin prevents CIPN.

PJ.2.1,Huge declines in learning across OECD countries, Norway doctors see 3x children with memory problems, Serum Cu/Zn ratio and Long COVID, 3rd Pennsylvania measles death, Psilocybin prevents CIPN.

PJ.2.1,Huge declines in learning across OECD countries, Norway doctors see 3x children with memory problems, Serum Cu/Zn ratio and Long COVID, 3rd Pennsylvania measles death, Psilocybin prevents CIPN.

Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling, often irreversible toxicity that affects millions of patients, limits life-saving cancer therapy, and lacks proven treatment. In this work, we show that as little as two doses of psilocybin before chemotherapy durably prevented the on …

PJ.2.1,Huge declines in learning across OECD countries, Norway doctors see 3x children with memory problems, Serum Cu/Zn ratio and Long COVID, 3rd Pennsylvania measles death, Psilocybin prevents CIPN.